Restructuring Costs

9 Months Ended

Sep. 30, 2013

Restructuring And Related Activities [Abstract]

10. RESTRUCTURING COSTS

In August 2013, the Company announced that its recently completed Phase 3 clinical trial of Allovectin^®, the Company’s investigational cancer immunotherapy, failed to meet the pre-established endpoints. As a result, the Company restructured its operations to conserve capital, which included a staff reduction of 47 employees and the write-off of certain intangible assets. The Company recorded charges for employee termination benefits of $2.2 million and for asset impairments of $0.7 million during the three months ended September 30, 2013. The following table summarizes the components of the restructuring charges for the three and nine months ended September 30, 2013 (in thousands):


	Three and Nine Months Ended September 30, 2013
	Accruals		Non-Cash Items		Total
Employee separation charges	$	2,208	$	—	$	2,208
Asset impairments		—		696		696

	$	2,208	$	696	$	2,904

The following table sets forth activity in the restructuring liability for the nine months ended September 30, 2013, which is wholly comprised of employee severance costs (in thousands):


	Accrued Severance
Balance at December 31, 2012	$	—
Accruals		2,208
Payments	$	(1,611	)

Balance at September 30, 2013	$	597

The balance of the accrued severance liability at September 30, 2013 is anticipated to be fully distributed by August 23, 2014.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details